API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.globenewswire.com/news-release/2024/05/02/2874077/0/en/Theratechnologies-to-Present-Long-Term-Efficacy-Safety-and-Pharmacokinetic-Data-on-Use-of-TH1902-sudocetaxel-zendusortide-in-Solid-Tumors-at-2024-ASCO-Meeting.html
https://www.globenewswire.com/news-release/2024/03/25/2851549/32419/en/Matinas-BioPharma-Announces-Positive-in-vivo-Safety-Data-with-its-Oral-LNC-Docetaxel-Formulation.html
https://www.indianpharmapost.com/news/venus-remedies-secures-marketing-approval-from-israel-colombia-for-two-oncology-drugs-15078
https://www.globenewswire.com//news-release/2023/12/04/2789883/0/en/Polaris-Group-Initiates-Phase-3-Trial-First-Patient-Successfully-Dosed-with-ADI-PEG-20-Placebo-plus-Gemcitabine-and-Docetaxel-for-Difficult-to-Treat-Leiomyosarcoma-LMS.html
https://www.globenewswire.com//news-release/2023/10/11/2758291/37149/en/PDS-Biotech-Announces-Interim-Safety-and-Immune-Response-Data-from-Phase-1-2-Clinical-Trial-Evaluating-Novel-Antibody-Drug-Conjugate-PDS0301-Combined-with-Docetaxel-to-Treat-Metast.html
https://www.onclive.com/view/frontline-zanidatamab-plus-docetaxel-yields-antitumor-activity-safety-in-advanced-her2-breast-cancer
https://www.globenewswire.com/news-release/2023/07/17/2705600/37149/en/PDS-Biotech-Announces-Acceptance-of-Abstract-on-Combination-of-PDS0301-with-Docetaxel-in-Metastatic-Prostate-Cancer-for-Oral-Presentation-by-the-National-Cancer-Institute-at-Cytoki.html
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/venus-remedies-gets-marketing-authorization-from-saudi-arabia-for-chemotherapy-drug-docetaxel/articleshow/100669448.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203892
https://www.globenewswire.com/news-release/2023/03/20/2629930/0/en/Darolutamide-approved-for-additional-prostate-cancer-indication-in-China.html
https://www.globenewswire.com/news-release/2023/03/01/2618152/0/en/BeyondSpring-Enrolls-First-Patient-in-Phase-2-Study-with-Plinabulin-Keytruda-and-Docetaxel-in-Patients-with-Metastatic-Non-Small-Cell-Lung-Cancer-Who-Progressed-After-Immunotherapy.html
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/alembic-pharma-gets-usfda-nod-to-market-generic-cancer-drug/articleshow/98332594.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://www.globenewswire.com/news-release/2023/01/27/2596803/0/en/Positive-CHMP-opinion-for-darolutamide-in-combination-with-docetaxel-for-the-treatment-of-metastatic-hormone-sensitive-prostate-cancer.html
https://www.globenewswire.com/news-release/2023/01/27/2596803/0/en/Positive-CHMP-opinion-for-darolutamide-in-combination-with-docetaxel-for-the-treatment-of-metastatic-hormone-sensitive-prostate-cancer.html
https://www.globenewswire.com/news-release/2022/12/13/2572669/0/en/BeyondSpring-Presents-Positive-Data-with-Plinabulin-for-the-Prevention-of-Docetaxel-Induced-Neutropenia-in-Patients-with-Non-Small-Cell-Lung-Cancer-and-Breast-Cancer-at-Three-Medic.html
https://www.biospace.com/article/exelixis-roche-combo-fails-to-improve-overall-survival-in-nsclc-/
https://www.clinicaltrialsarena.com/news/lyvgen-bms-cancer-antibody-trial/
https://www.prnewswire.com/news-releases/chemotherapy-may-be-completed-within-8-days-with-two-doses-of-polytaxel-an-innovative-anticancer-drug-from-south-koreas-biotech-firm-301687078.html
https://www.bayer.com/en/ca/health-canada-approves-additional-indication-for-nubeqar
https://www.prnewswire.com/news-releases/lumakraslumykras-sotorasib-demonstrates-superior-progression-free-survival-over-docetaxel-in-first-positive-phase-3-trial-of-a-kras-g12c-inhibitor-in-non-small-cell-lung-cancer-301621632.html
https://www.bayer.com/media/en-us/new-arasens-data-reinforce-strong-tolerability-profile-of-darolutamide-plus-adt-and-docetaxel-without-compromising-quality-of-life-for-patients-with-mhspc/
https://www.fiercepharma.com/pharma/look-out-pfizer-bayers-nubeqa-coming-xtandis-prostate-cancer-crown
https://www.globenewswire.com/news-release/2022/08/08/2493531/0/en/U-S-FDA-approves-additional-indication-of-darolutamide-in-combination-with-docetaxel-for-the-treatment-of-metastatic-hormone-sensitive-prostate-cancer-mHSPC.html
https://media.bayer.com/baynews/baynews.nsf/id/Darolutamide-androgen-deprivation-therapy-docetaxel-demonstrates-consistent-overall-survival?OpenDocument&sessionID=1660127120
https://www.prnewswire.com/news-releases/neotx-announces-successful-first-stage-completion-of-its-phase-2a-clinical-trial-of-naptumomab-estafenatox-nap-in-combination-with-docetaxel-in-advanced-non-small-cell-lung-cancer-nsclc-301558939.html
https://www.prnewswire.com/news-releases/akeso-announces-ind-approval-from-china-nmpa-for-phase-ii-clinical-trial-of-cadonilimab-in-combination-with-docetaxel-to-treat-nsclc-301497348.html
https://www.globenewswire.com/news-release/2022/02/23/2389999/0/en/Update-on-Progress-of-SAKK-Investigator-Initiated-Phase-1b-trial-of-Docetaxel-Micellar-in-Advanced-Prostate-Cancer.html
https://www.globenewswire.com/news-release/2022/02/21/2388723/0/en/LIDDS-Next-Step-with-NanoZolid-formulated-docetaxel.html
https://www.pharmatimes.com/news/data_day_trial_results_deliver_hope_for_prostate_cancer_patients_1387889
https://endpts.com/appeals-court-quashes-sanofis-big-win-on-bellwether-hair-loss-case/
https://www.fiercepharma.com/pharma/bayer-pads-blockbuster-case-for-nubeqa-metastatic-prostate-cancer-win
http://www.pharmafile.com/news/597952/arasens-phase-iii-trial-prostate-cancer-treatment-meets-primary-endpoint
https://www.globenewswire.com/news-release/2021/12/03/2345595/0/en/ARASENS-trial-with-darolutamide-in-combination-with-docetaxel-and-androgen-deprivation-therapy-meets-primary-endpoint-of-significantly-increasing-overall-survival-in-patients-with-.html
https://news.bloomberglaw.com/class-action/sanofi-wins-second-test-trial-in-taxotere-cancer-drug-litigation
https://www.evaluate.com/vantage/articles/news/snippets/esmo-2021-beyondspring-experiences-winter-discontent
https://www.globenewswire.com/news-release/2021/09/20/2299673/0/en/BeyondSpring-Pharmaceuticals-Announces-Positive-Final-Phase-3-DUBLIN-3-Data-with-the-Plinabulin-Docetaxel-Combination-versus-Docetaxel-Alone-in-2nd-3rd-Line-Non-Small-Cell-Lung-Can.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213510
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214575
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-16-2020-1608097779.pdf
https://medicalxpress.com/news/2020-07-popular-chemotherapy-drug-effective-overweight.html
https://www.oasmia.com/en/oasmia-pharmaceutical-ab-signs-phase-1b-trial-agreement-with-sakk-the-swiss-group-for-clinical-cancer-research-for-evaluation-of-docetaxel-micellar/